Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Biochemical and biophysical characterization of purified native CD20 alone and in complex with rituximab and obinutuzumab.

Agez M, Mandon ED, Iwema T, Gianotti R, Limani F, Herter S, Mössner E, Kusznir EA, Huber S, Lauer M, Ringler P, Ferrara C, Klein C, Jawhari A.

Sci Rep. 2019 Sep 23;9(1):13675. doi: 10.1038/s41598-019-50031-4.

2.

P329G-CAR-J: a novel Jurkat-NFAT-based CAR-T reporter system recognizing the P329G Fc mutation.

Darowski D, Jost C, Stubenrauch K, Wessels U, Benz J, Ehler A, Freimoser-Grundschober A, Brünker P, Mössner E, Umaña P, Kobold S, Klein C.

Protein Eng Des Sel. 2019 Sep 3. pii: gzz027. doi: 10.1093/protein/gzz027. [Epub ahead of print]

PMID:
31504896
3.

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Claus C, Ferrara C, Xu W, Sam J, Lang S, Uhlenbrock F, Albrecht R, Herter S, Schlenker R, Hüsser T, Diggelmann S, Challier J, Mössner E, Hosse RJ, Hofer T, Brünker P, Joseph C, Benz J, Ringler P, Stahlberg H, Lauer M, Perro M, Chen S, Küttel C, Bhavani Mohan PL, Nicolini V, Birk MC, Ongaro A, Prince C, Gianotti R, Dugan G, Whitlow CT, Solingapuram Sai KK, Caudell DL, Burgos-Rodriguez AG, Cline JM, Hettich M, Ceppi M, Giusti AM, Crameri F, Driessen W, Morcos PN, Freimoser-Grundschober A, Levitsky V, Amann M, Grau-Richards S, von Hirschheydt T, Tournaviti S, Mølhøj M, Fauti T, Heinzelmann-Schwarz V, Teichgräber V, Colombetti S, Bacac M, Zippelius A, Klein C, Umaña P.

Sci Transl Med. 2019 Jun 12;11(496). pii: eaav5989. doi: 10.1126/scitranslmed.aav5989.

PMID:
31189721
4.

GA101 P329GLALA, a variant of obinutuzumab with abolished ADCC, ADCP and CDC function but retained cell death induction, is as efficient as rituximab in B-cell depletion and antitumor activity.

Herter S, Herting F, Muth G, van Puijenbroek E, Schlothauer T, Ferrara C, Brady K, Lang S, Bacac M, Mössner E, Umana P, Klein C.

Haematologica. 2018 Feb;103(2):e78-e81. doi: 10.3324/haematol.2017.178996. Epub 2017 Oct 27. No abstract available.

5.

Novel human IgG1 and IgG4 Fc-engineered antibodies with completely abolished immune effector functions.

Schlothauer T, Herter S, Koller CF, Grau-Richards S, Steinhart V, Spick C, Kubbies M, Klein C, Umaña P, Mössner E.

Protein Eng Des Sel. 2016 Oct;29(10):457-466. doi: 10.1093/protein/gzw040. Epub 2016 Aug 29.

PMID:
27578889
6.

RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.

Brünker P, Wartha K, Friess T, Grau-Richards S, Waldhauer I, Koller CF, Weiser B, Majety M, Runza V, Niu H, Packman K, Feng N, Daouti S, Hosse RJ, Mössner E, Weber TG, Herting F, Scheuer W, Sade H, Shao C, Liu B, Wang P, Xu G, Vega-Harring S, Klein C, Bosslet K, Umaña P.

Mol Cancer Ther. 2016 May;15(5):946-57. doi: 10.1158/1535-7163.MCT-15-0647. Epub 2016 Apr 1.

7.

Response to: monoclonal antibodies targeting CD20.

Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, Hopfner KP, Umaña P, Niederfellner G.

MAbs. 2013 May-Jun;5(3):337-8. doi: 10.4161/mabs.24108. Epub 2013 Mar 14. No abstract available.

8.

Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties.

Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, Hopfner KP, Umaña P, Niederfellner G.

MAbs. 2013 Jan-Feb;5(1):22-33. doi: 10.4161/mabs.22771. Epub 2012 Dec 4.

9.

Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies.

Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, Franke A, Wiechmann K, Jenewein S, Slootstra JW, Timmerman P, Brännström A, Lindstrom F, Mössner E, Umana P, Hopfner KP, Klein C.

Blood. 2011 Jul 14;118(2):358-67. doi: 10.1182/blood-2010-09-305847. Epub 2011 Mar 28.

PMID:
21444918
10.

Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity.

Mössner E, Brünker P, Moser S, Püntener U, Schmidt C, Herter S, Grau R, Gerdes C, Nopora A, van Puijenbroek E, Ferrara C, Sondermann P, Jäger C, Strein P, Fertig G, Friess T, Schüll C, Bauer S, Dal Porto J, Del Nagro C, Dabbagh K, Dyer MJ, Poppema S, Klein C, Umaña P.

Blood. 2010 Jun 3;115(22):4393-402. doi: 10.1182/blood-2009-06-225979. Epub 2010 Mar 1.

11.

Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis.

Ashraf SQ, Umana P, Mössner E, Ntouroupi T, Brünker P, Schmidt C, Wilding JL, Mortensen NJ, Bodmer WF.

Br J Cancer. 2009 Nov 17;101(10):1758-68. doi: 10.1038/sj.bjc.6605355.

12.

Severe neurological impairment in hereditary methaemoglobinaemia type 2.

Toelle SP, Boltshauser E, Mössner E, Zurbriggen K, Eber S.

Eur J Pediatr. 2004 Apr;163(4-5):207-9. Epub 2004 Feb 18.

PMID:
14986124
13.
14.
15.

Importance of redox potential for the in vivo function of the cytoplasmic disulfide reductant thioredoxin from Escherichia coli.

Mössner E, Huber-Wunderlich M, Rietsch A, Beckwith J, Glockshuber R, Aslund F.

J Biol Chem. 1999 Sep 3;274(36):25254-9.

17.
18.

The analytical and clinical performance of the new Boehringer Mannheim Enzymun-Test PSA assay for prostate-specific antigen.

Blijenberg BG, Eman I, Boevé ER, Mössner E, Uhl W.

Eur J Clin Chem Clin Biochem. 1995 Jun;33(6):383-92.

PMID:
7578619
19.

Placental alkaline phosphatase in tumour tissue and serum.

Mössner E, Pfleiderer G, Dittel KD.

J Clin Chem Clin Biochem. 1984 Jul;22(7):467-71.

PMID:
6481309
20.
21.

Solid-phase direct immunoassay for serum intestinal and placental alkaline phosphatase.

Mössner E, Pfleiderer G.

Clin Biochem. 1983 Feb;16(1):28-30.

PMID:
6861336
22.

Purification of human and bovine alkaline phosphatases by affinity chromatography.

Mössner E, Boll M, Pfleiderer G.

Hoppe Seylers Z Physiol Chem. 1980 Apr;361(4):543-9. No abstract available.

PMID:
7380395
23.

The continental reception of Hume's treatise, 1739-1741.

MOSSNER EC.

Mind. 1947 Jan;56(221):31-43. No abstract available.

PMID:
20285972

Supplemental Content

Loading ...
Support Center